Challenges of the new gene therapy era: a focus on CAR T-cell treatment

CAR T-cell therapies entered the immunotherapy field in 2017 with the FDA approval of Kymriah and Yescarta for haematological malignancies. Marianna Sciortino, Associate Director, Diaceutics, assesses the current and unique challenges of this innovative and life-changing new treatment option, and considers the issues it raises for regulation and reimbursement in the US and European markets.
Existing Users Log In